Pharming Group (NASDAQ:PHAR) Shares Down 3.6% - Should You Sell?

Pharming Group (NASDAQ:PHAR - Get Free Report) traded down 3.6% during trading on Monday . The stock traded as low as $8.80 and last traded at $8.63. 2,744 shares changed hands during trading, a decline of 56% from the average session volume of 6,183 shares. The stock had previously closed at $8.95.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Oppenheimer upped their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th. Jefferies Financial Group started coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a "buy" rating and a $14.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday.

Pharming Group Stock Performance

The stock has a market capitalization of $590.17 million, a PE ratio of -33.37 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business's fifty day moving average price is $8.91 and its 200-day moving average price is $8.61.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). The company had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, equities research analysts expect that Pharming Group will post -0.2 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.